The Medicines and Healthcare products Regulatory Agency grants conditional authorisation of the Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients, making the United Kingdom the first country to approve the world's first antiviral oral drug.
The Medicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients, making the United Kingdom the first country to approve the world's firstCOVID-19 antiviral oral drug.
